Literature DB >> 12841350

Activation of peroxisome proliferator-activated receptors alpha and gamma1 inhibits human smooth muscle cell proliferation.

Peter Zahradka1, Natalia Yurkova, Brenda Litchie, Michael C Moon, Dario F Del Rizzo, Carla G Taylor.   

Abstract

Atherosclerotic lesions occur as a result of excess lipid deposition within the vascular tissues. The peroxisome proliferator-activated receptors (PPARs) present in adipose and hepatic tissues have been shown to promote fatty acid oxidation and lipid storage. An immunohistochemical assessment of PPARalpha and PPARgamma revealed both proteins were also present in the medial and intimal layers of human arteries, predominately in regions containing smooth muscle cells. In agreement with this observation, smooth muscle cells isolated from these vessels were found by RT-PCR to express both PPARalpha and PPARgamma1. The functionality of these receptors was tested with selective PPAR agonists. Mitogenic stimulation of smooth muscle cell proliferation was blocked by 15d-PGJ2, a PPARgamma agonist, as well as by WY14643, a PPARalpha agonist. These data indicate PPAR activation by selective agonists could influence lesion progression directly, as well as indirectly through reductions in serum lipoprotein and triglyceride levels.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12841350

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  33 in total

1.  Nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha) is expressed in resting murine lymphocytes. The PPARalpha in T and B lymphocytes is both transactivation and transrepression competent.

Authors:  Dallas C Jones; Xiaohong Ding; Raymond A Daynes
Journal:  J Biol Chem       Date:  2001-11-28       Impact factor: 5.157

2.  15-Deoxy-Delta(12,14)-prostaglandin J(2) induces G(1) arrest and differentiation marker expression in vascular smooth muscle cells.

Authors:  Y Miwa; T Sasaguri; H Inoue; Y Taba; A Ishida; T Abumiya
Journal:  Mol Pharmacol       Date:  2000-10       Impact factor: 4.436

3.  Discordant hepatic expression of the cell division control enzyme p34cdc2 kinase, proliferating cell nuclear antigen, p53 tumor suppressor protein, and p21Waf1 cyclin-dependent kinase inhibitory protein after WY14,643 ([4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid) dosing to rats.

Authors:  X Ma; D A Stoffregen; G D Wheelock; J A Rininger; J G Babish
Journal:  Mol Pharmacol       Date:  1997-01       Impact factor: 4.436

4.  PPARalpha activators inhibit tissue factor expression and activity in human monocytes.

Authors:  N Marx; N Mackman; U Schönbeck; N Yilmaz; V Hombach; P Libby; J Plutzky
Journal:  Circulation       Date:  2001-01-16       Impact factor: 29.690

Review 5.  Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall.

Authors:  G Chinetti; J C Fruchart; B Staels
Journal:  Z Kardiol       Date:  2001

6.  Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice.

Authors:  A C Li; K K Brown; M J Silvestre; T M Willson; W Palinski; C K Glass
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

7.  Peroxisome proliferator-activated receptor (PPAR)-gamma expression in human vascular smooth muscle cells: inhibition of growth, migration, and c-fos expression by the peroxisome proliferator-activated receptor (PPAR)-gamma activator troglitazone.

Authors:  S Benson; J Wu; S Padmanabhan; T W Kurtz; H A Pershadsingh
Journal:  Am J Hypertens       Date:  2000-01       Impact factor: 2.689

8.  Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation.

Authors:  S S Palakurthi; H Aktas; L M Grubissich; R M Mortensen; J A Halperin
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

9.  Docosahexaenoic acid, a peroxisome proliferator-activated receptor-alpha ligand, induces apoptosis in vascular smooth muscle cells by stimulation of p38 mitogen-activated protein kinase.

Authors:  Q N Diep; R M Touyz; E L Schiffrin
Journal:  Hypertension       Date:  2000-11       Impact factor: 10.190

10.  Effect of etofibrate on the development and the regression of atheromas in a rabbit model of atherosclerosis.

Authors:  E Betz; G Quack
Journal:  Vasa       Date:  1990       Impact factor: 1.961

View more
  6 in total

1.  Localization of cannabinoid receptors CB1, CB2, GPR55, and PPARα in the canine gastrointestinal tract.

Authors:  Giorgia Galiazzo; Fiorella Giancola; Agnese Stanzani; Federico Fracassi; Chiara Bernardini; Monica Forni; Marco Pietra; Roberto Chiocchetti
Journal:  Histochem Cell Biol       Date:  2018-06-07       Impact factor: 4.304

2.  MicroRNA-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration.

Authors:  Joy Sarkar; Deming Gou; Prasanna Turaka; Ekaterina Viktorova; Ramaswamy Ramchandran; J Usha Raj
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-08-06       Impact factor: 5.464

3.  PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a.

Authors:  Florence Gizard; Carole Amant; Olivier Barbier; Stefano Bellosta; Romain Robillard; Frédéric Percevault; Henry Sevestre; Paul Krimpenfort; Alberto Corsini; Jacques Rochette; Corine Glineur; Jean-Charles Fruchart; Gérard Torpier; Bart Staels
Journal:  J Clin Invest       Date:  2005-11       Impact factor: 14.808

4.  Conjugated linoleic acid reduces hepatic steatosis, improves liver function, and favorably modifies lipid metabolism in obese insulin-resistant rats.

Authors:  Amy Noto; Peter Zahradka; Natalia Yurkova; Xueping Xie; Evan Nitschmann; Malcolm Ogborn; Carla G Taylor
Journal:  Lipids       Date:  2006-02       Impact factor: 1.880

Review 5.  PPARs and the cardiovascular system.

Authors:  Milton Hamblin; Lin Chang; Yanbo Fan; Jifeng Zhang; Y Eugene Chen
Journal:  Antioxid Redox Signal       Date:  2009-06       Impact factor: 8.401

6.  Atheroprotective effect of oleoylethanolamide (OEA) targeting oxidized LDL.

Authors:  Angran Fan; Xiaofeng Wu; Huijuan Wu; Long Li; Rui Huang; Yueyong Zhu; Yan Qiu; Jin Fu; Jie Ren; Chenggang Zhu
Journal:  PLoS One       Date:  2014-01-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.